Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was ...
Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted therapy in clear cell ...
4d
Its new cancer drug makes cells self-destruct. Investors bet another $100M on this San Diego startup
Since its founding in 2020, Neomorph has inked nearly $5 billion worth of deals with pharmaceutical companies.
Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...
Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...
Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. AbbVie will pay ...
SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc., a venture backed biotechnology company solving critical problems in human health through the discovery and development of innovative new medicines against ...
SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...
SAN DIEGO, April 14, 2026 (GLOBE NEWSWIRE)-- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results